Literature DB >> 26293676

Synchronous glioblastoma and medulloblastoma in a child with mismatch repair mutation.

Nisreen Amayiri1, Maysa Al-Hussaini2, Maisa Swaidan3, Imad Jaradat4, Monther Qandeel3, Uri Tabori5, Cynthia Hawkins6, Awni Musharbash7, Khulood Alsaad8, Eric Bouffet5.   

Abstract

Synchronous primary malignant brain tumors are rare. We present a 5-year-old boy with synchronous glioblastoma and medulloblastoma. Both tumor samples had positive p53 stain and loss of PMS2 and MLH1 stains. The child had multiple café au lait spots and a significant family history of cancer. After subtotal resection of both tumors, he received craniospinal radiation with concomitant temozolomide followed by chemotherapy, alternating cycles of cisplatin/lomustine/vincristine with temozolomide. Then, he started maintenance treatment with cis-retinoic acid (100 mg/m(2)/day for 21 days). He remained asymptomatic for 34 months despite a follow-up brain MRI consistent with glioblastoma relapse 9 months before his death. Cis-retinoic acid may have contributed to prolong survival in this child with a probable biallelic mismatch repair syndrome.

Entities:  

Keywords:  Biallelic mismatch repair syndrome; Cis-retinoic acid; Glioblastoma; Synchronous tumors

Mesh:

Substances:

Year:  2015        PMID: 26293676     DOI: 10.1007/s00381-015-2883-3

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  27 in total

1.  Is mismatch repair really required for ionizing radiation-induced DNA damage signaling?

Authors:  Petr Cejka; Lovorka Stojic; Giancarlo Marra; Josef Jiricny
Journal:  Nat Genet       Date:  2004-05       Impact factor: 38.330

2.  All-trans retinoic acid modulates cancer stem cells of glioblastoma multiforme in an MAPK-dependent manner.

Authors:  Michael Karsy; Ladislau Albert; Michael E Tobias; Raj Murali; Meena Jhanwar-Uniyal
Journal:  Anticancer Res       Date:  2010-12       Impact factor: 2.480

3.  High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan.

Authors:  Nisreen Amayiri; Uri Tabori; Brittany Campbell; Doua Bakry; Melyssa Aronson; Carol Durno; Patricia Rakopoulos; David Malkin; Ibrahim Qaddoumi; Awni Musharbash; Maisa Swaidan; Eric Bouffet; Cynthia Hawkins; Maysa Al-Hussaini
Journal:  Int J Cancer       Date:  2015-08-21       Impact factor: 7.396

4.  Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium.

Authors:  Doua Bakry; Melyssa Aronson; Carol Durno; Hala Rimawi; Roula Farah; Qasim Kholaif Alharbi; Musa Alharbi; Ashraf Shamvil; Shay Ben-Shachar; Matthew Mistry; Shlomi Constantini; Rina Dvir; Ibrahim Qaddoumi; Steven Gallinger; Jordan Lerner-Ellis; Aaron Pollett; Derek Stephens; Steve Kelies; Elizabeth Chao; David Malkin; Eric Bouffet; Cynthia Hawkins; Uri Tabori
Journal:  Eur J Cancer       Date:  2014-01-15       Impact factor: 9.162

5.  Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide.

Authors:  José L McFaline-Figueroa; Christian J Braun; Monica Stanciu; Zachary D Nagel; Patrizia Mazzucato; Dewakar Sangaraju; Edvinas Cerniauskas; Kelly Barford; Amanda Vargas; Yimin Chen; Natalia Tretyakova; Jacqueline A Lees; Michael T Hemann; Forest M White; Leona D Samson
Journal:  Cancer Res       Date:  2015-05-29       Impact factor: 12.701

6.  Hypothesis: Possible role of retinoic acid therapy in patients with biallelic mismatch repair gene defects.

Authors:  Sven Gottschling; Harald Reinhard; Constanze Pagenstecher; Stefan Krüger; Jochen Raedle; Guido Plotz; Wolfram Henn; Reinhard Buettner; Sascha Meyer; Norbert Graf
Journal:  Eur J Pediatr       Date:  2007-03-27       Impact factor: 3.183

7.  Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.

Authors:  Kenneth J Cohen; Ian F Pollack; Tianni Zhou; Allen Buxton; Emiko J Holmes; Peter C Burger; Daniel J Brat; Marc K Rosenblum; Ronald L Hamilton; Robert S Lavey; Richard L Heideman
Journal:  Neuro Oncol       Date:  2011-03       Impact factor: 12.300

8.  Evaluation of retinoic acid therapy for OTX2-positive medulloblastomas.

Authors:  Renyuan Bai; I-Mei Siu; Betty M Tyler; Verena Staedtke; Gary L Gallia; Gregory J Riggins
Journal:  Neuro Oncol       Date:  2010-02-05       Impact factor: 12.300

9.  Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium "Care for CMMR-D" (C4CMMR-D).

Authors:  H F A Vasen; Z Ghorbanoghli; F Bourdeaut; O Cabaret; O Caron; A Duval; N Entz-Werle; Y Goldberg; D Ilencikova; C P Kratz; N Lavoine; J Loeffen; F H Menko; M Muleris; G Sebille; C Colas; B Burkhardt; L Brugieres; K Wimmer
Journal:  J Med Genet       Date:  2014-02-20       Impact factor: 6.318

Review 10.  Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD).

Authors:  Katharina Wimmer; Christian P Kratz; Hans F A Vasen; Olivier Caron; Chrystelle Colas; Natacha Entz-Werle; Anne-Marie Gerdes; Yael Goldberg; Denisa Ilencikova; Martine Muleris; Alex Duval; Noémie Lavoine; Clara Ruiz-Ponte; Irene Slavc; Brigit Burkhardt; Laurence Brugieres
Journal:  J Med Genet       Date:  2014-04-15       Impact factor: 6.318

View more
  5 in total

1.  Constitutional mismatch repair deficiency-associated brain tumors: report from the European C4CMMRD consortium.

Authors:  Léa Guerrini-Rousseau; Pascale Varlet; Chrystelle Colas; Felipe Andreiuolo; Franck Bourdeaut; Karin Dahan; Christine Devalck; Cécile Faure-Conter; Maurizio Genuardi; Yael Goldberg; Michaela Kuhlen; Salma Moalla; Enrico Opocher; Vanessa Perez-Alonso; Astrid Sehested; Irene Slavc; Sheila Unger; Katharina Wimmer; Jacques Grill; Laurence Brugières
Journal:  Neurooncol Adv       Date:  2019-12-02

2.  Primary cervical glioblastoma multiforme as a presentation of constitutional mismatch repair deficiency: Case report and literature review.

Authors:  Sultan M Jarrar; Suleiman S Daoud; Omar F Jbarah; Iyad S Albustami; Moh'd Alamin Daise
Journal:  Ann Med Surg (Lond)       Date:  2021-03-27

3.  Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy.

Authors:  Mohammed G Ghonime; Uksha Saini; Michael C Kelly; Justin C Roth; Pin-Yi Wang; Chun-Yu Chen; Katherine Miller; Ilse Hernandez-Aguirre; Yeaseul Kim; Xiaokui Mo; Joseph R Stanek; Tim Cripe; Elaine Mardis; Kevin A Cassady
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 12.469

4.  Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study.

Authors:  Jacob J Henderson; Anirban Das; Daniel A Morgenstern; Sumedha Sudhaman; Vanessa Bianchi; Jill Chung; Logine Negm; Melissa Edwards; David E Kram; Michael Osborn; Cynthia Hawkins; Eric Bouffet; Yoon-Jae Cho; Uri Tabori
Journal:  JCO Precis Oncol       Date:  2022-03

Review 5.  Immunotherapeutic Challenges for Pediatric Cancers.

Authors:  Brian Hutzen; Mohammed Ghonime; Joel Lee; Elaine R Mardis; Ruoning Wang; Dean A Lee; Mitchell S Cairo; Ryan D Roberts; Timothy P Cripe; Kevin A Cassady
Journal:  Mol Ther Oncolytics       Date:  2019-08-28       Impact factor: 7.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.